LASIX

Compare LASIX  to:
Compare
Compare

Generic Name for LASIX

Furosemide 20mg, 40mg+, 80mg; tabs; +scored.

Legal Classification:

Rx

Pharmacological Class for LASIX

Diuretic (loop).

Manufacturer of LASIX

Sanofi Aventis

Indications for LASIX

Hypertension.

Adult dose for LASIX

Initially 40mg twice daily. Adding to other antihypertensives: initially reduce other agent's dose by 50%.

Children's dosing for LASIX

Not recommended.

Contraindications for LASIX

Anuria. Hepatic coma. Electrolyte depletion.

Precautions for LASIX

Renal or hepatic dysfunction. Diabetes. Gout. SLE. Sulfonamide sensitivity. Monitor BP, electrolytes, fluids, blood, BUN. Potassium supplementation may be needed. Discontinue if progressive renal dysfunction occurs. Elderly. Pregnancy (Cat.C). Nursing mothers.

Interactions for LASIX

Digitalis, lithium toxicity. Alcohol, CNS depressants may increase orthostatic hypotension. Antagonized by indomethacin. May alter excretion of salicylates, lithium. Hypokalemia with corticosteroids, ACTH. Antagonizes tubocurarine. Potentiates antihypertensives, succinylcholine. Ototoxicity with aminoglycosides, ethacrynic acid.

Adverse Reactions for LASIX

Excessive diuresis, fluid or electrolyte imbalance, GI upset, dizziness, vertigo, paresthesias, orthostatic hypotension, hyperglycemia, jaundice, hyperuricemia, rash, photosensitivity, tinnitus, hearing loss, blood dyscrasias, renal calcification in premature infants.

How is LASIX supplied?

Tabs 20mg—100, 1000
40mg—100, 500, 1000
80mg—50, 500

Related Disease:

Hypertension

Related Resources

FDA warns of reduced Plavix efficacy in poor metabolizers

March 15, 2010

The FDA has notified healthcare professionals and patients that a Boxed Warning has been added to the Plavix (clopidogrel tablets, from Bristol-Myers Squibb and Sanofi) Prescribing Information to include information about reduced Plavix efficacy in patients who are poor metabolizers of Plavix.

Benicar gains expanded indication for treatment of hypertension in children

February 11, 2010

The FDA has approved Benicar (olmesartan medoxomil tablets, from Daiichi Sankyo) for the treatment of hypertension in children and adolescents 6-16 years of age.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Cleviprex injection recalled due to presence of particulate matter

December 17, 2009

The FDA and The Medicines Company have notified healthcare professionals of a voluntary nationwide recall of 11 lots of Cleviprex (clevidipine butyrate) injection emulsion due to the presence of visible particulate matter observed in some vials.

Clonidine ER Suspension and Clonidine ER Tablets approved

December 07, 2009

Tris Pharma announced that the FDA has approved Clonidine ER suspension and Clonidine ER tablets, both of which utilize its proprietary OralXR+ platform technology to allow for once daily dosing.